CSF3 and breast cancer: Clinical data from several studies show that taxane therapy increases serum IL-6 and G-CSF levels in patients [53,54] and that higher levels of serum IL-6 is a prognostic marker for early breast cancer recurrence in patients receiving systemic therapy [55,56].